Alebund Pharmaceuticals (Jiangsu) Limited (HKG:9637)

HKG:9637 Ratios and Metrics

Market cap in millions HKD. Fiscal year is January - December.

Financial Efficiency

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Oct 6, 2026	Dec 31, 2025	Dec 31, 2024
Debt / Equity Ratio	0.41	1.09	-0.36
Net Debt / Equity Ratio	-0.58	0.04	-0.08
Net Debt / EBITDA Ratio	1.40	-0.03	-0.37
Net Debt / FCF Ratio	2.02	-0.04	-0.23
Asset Turnover	-	0.03	-
Inventory Turnover	-	2.09	-
Quick Ratio	9.70	2.22	0.19
Current Ratio	9.81	2.33	0.20
Return on Assets (ROA)	-	-33.01%	-
Return on Capital Employed (ROCE)	-30.90%	-58.80%	37.20%

Yields

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Oct 6, 2026	Dec 31, 2025	Dec 31, 2024
Buyback Yield / Dilution	-	10.08%	-

Data Source: S&P Global Market Intelligence Last updated: Sep 17, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 6, 2026

Data Sources Report a data error